MedPath

Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Insulin in Patients with Type 2 Diabetes

Phase 3
Conditions
Type 2 diabetes
Registration Number
JPRN-jRCT2080222199
Lead Sponsor
SANWA KAGAKU KENKYUSHO CO.,LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Male
Target Recruitment
Not specified
Inclusion Criteria

Patients with type 2 diabetes who have inadequate glycemic control on insulin therapy
HbA1c(NGSP) of >= 6.9%, but < 11.0% measured during the run-in period

Exclusion Criteria

Patients with type 1 diabetes mellitus
Patients with severe hypoglycemia or recurrent asymptomatic hypoglycemia
Patients with, or a history of, clinically significant cardiac, renal, hepatic, pulmonary, pancreatic and macrovascular disease
Patients have a known allergy or hypersensitivity to insulin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath